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Summary.  
Chronic Myeloid Leukaemia (CML) is a blood-derived proliferative disorder, which is 
highly associated to a translocation of chromosomes 9 and 22 or the creation of 
Philadelphia chromosome Ph(+) cases, inducing the synthesis of a chimeric fusion 
protein, namely BCR-ABL1 (Breakpoint Cluster Region-Abelson 1 chimeric protein), 
which is known for driving the pathophysiology of the disease, however variants of CML 
are also recognized as CML Ph(-), these nonetheless account for a small percentage of 
the overall CML patients; posing thus the question whether BCR-ABL1 fusion protein is 
required for the whole of the pathophysiology of CML. Hereof, through a stochastic 
description, a discrete time discrete Markov chain depicts the various protein-protein 
interactions of BCR-ABL1 to better understand signalling pathways and time-dependent 
evolution of these pathways, as well as to provide prospective therapeutic protein targets 
to improve both the specificity of the treatment and the life-expectancy of the patients.  
 
 
 
 
 
 
 
 
 
 
Background. 
Definition.  
Chronic myeloid leukaemia (CML) is a blood cancer in which there is an abnormal 
proliferation of myeloid-derived cells, such as neutrophils, basophils, eosinophils, mast 
cells, monocytes; this pathology is classically associated to a translocation in the 
chromosomes 9 and 22 t(9;22) showing afterwards the expression of a fusion protein, 
BCR-ABL protein, ABL1 from the Abelson protein portion on chromosome 9 and BCR 
from the breakpoint cluster region on chromosome 22 (Jabbour & Kantarijan, 2018), 
BCR-ABL-negative cases of chronic myeloid leukaemia have been reported and account 
for around 1 to 2% of the CML cases, in which there exist various genetic aberrations, 
such as: mutations in CSF3R, SETBP1, JAK2V617F, KRAS, NRAS (Giri, Pathak, Martin, 
& Bhatt, 2015), although this could be disputed due to the fact that these patients show 
genetic instability thus, the translocation could vary in time (Balk, Fabarius, & Haferlach, 
2016).  
Epidemiology.  
The incidence of CML varies from 4 per million people in non-Western countries to 1.75 
per 100,000 people in the USA, this variation could be due the fact that BCR-ABL 
negative clones are sometimes not taken in account as CML cases. The incidence shows 
an increase with corresponding increasing age, for it has been shown that in some 
European countries the median age of diagnosis is from 57-60 years, nevertheless cases 
have been seen from 15 years to more than 85 years of age, with two peaks of age at 
diagnosis in the intervals from 70 to 74 years and from 80 to 84 years.  
The prevalence has been reported from 5.6 to 7.3 per 100,000 inhabitants (Höglund, 
Sandin, & Simonsson, 2015), and estimations have been made in order to predict the 
prevalence in upcoming years  which show a prevalence of 140,000 patients in 2030 and 
of 180,000 patients in 2050 in the USA alone, showing then an increase in the prevalence 
(Huang, Cortes, & Kantarijan, 2012).  
Risk factors have been associated to CML, such as the exposure to ionising radiation as 
it has been seen in people who survived the atomic bomb in Hiroshima (Hehlmann, 
Hochhaus, & Baccarani, 2007) and in people in whom it has been performed both 
radiography and tomography in repeated occasions (Ju, et al., 2016). In regards to 
chemicals, a meta-analysis showed that there exists no relationship between benzene 
and CML development, with a 𝑂𝑅 = 1.003 (Lamm, Engel, Joshi, Byrd III, & Chen, 2009). 
Another study showed the potential relationship in a dose-dependent manner between 
cigarette smoking and CML development, with a OR increasing with the increasing 
amount of pack-years, however there is no overall relationship between the smokers vs. 
non-smokers group in CML development (Qin, Deng, Chen, & Wei, 2016). The overall 
risk of developing CML is greater in males than in females with a male-to-female ratio 
which varies from 1.2 to 1.7 (Höglund, Sandin, & Simonsson, 2015).  
Pathophysiology.  
As in the previous remarks it has been seen, one of the main features of CML is the 
phenomenon of translocation of the chromosomes 9 and 22, i.e., t(9;22)(q34;q11) then 
adjoining two distinct genes, the BCR gene (breakpoint cluster region) and ABL1 gene 
(Abelson), this juxtaposition occurs most of the occasions at the intro 13 or 14 of BCR 
and the exons 1b and 2 of ABL1 (Chereda & Melo, 2016) however different juxtaposition 
regions have been observed, such as in the intron 14 of BCR and the intron 2 of ABL1 
(Lyu, et al., 2016) and many others: b3a2, b2a2, b3a3, b2a3, e1a2, 19a2 (Melo, 1996).  
The BCR gene is located at 22q11.23, and shows 23 exons and it is expressed widely 
throughout the body, it has been associated to both acute as well as to chronic myeloid 
leukemia (NIH, 2019), this BCR gene encodes two RNA species of 4.5 and 6.7 kbp, and 
its promoter region contains SP1 binding sites, it has been proposed to have a role in 
metabolism; the translated protein product is a phosphoprotein with serine/threonine 
kinase activity as well as phosphotransferase activity, this activity has been confirmed 
with the homologies it shows in regards to other kinases (Maru & Witte, 1991). Some of 
its molecular interactions are shown in Table 1 (TyersLab, 2019), and we may postulate 
six sets of types of molecules with which it interacts: signal processing (P), cell trafficking 
(T), cell growth (G), cell proliferation (Pr), metabolism (M), structure (S) however these 
sets show obvious overlap, 𝑃 ∩𝑀 ≠ ∅ ∧ 𝑆 ∩ 𝑇 ≠ ∅ ∧ 𝑃 ∩ 𝑃𝑟 ≠ ∅ (Table 1).  
ABL1 in turn is a protooncogene with tyrosine kinase activity which is involved in several 
cellular processes: cell division, adhesion, differentiation, response to stress. The activity 
of ABL1 protein is negatively regulated by its SH3 domain. It is displayed in various types 
of leukaemias. Possesses 12 exons (NIH, 2019).  
The resulting fusion protein BCR-ABL1 is a 210 kDa protein, and sometimes it could be 
detected in healthy individuals hypothesizing the lack of potency in the transformed cell 
to support leukaemia (Ismail, Naffa, Yousef, & Ghanim, 2014). The domains in BCR-
ABL1 which appear to affect the protein function are the Ser/Thr kinase domain 
pertaining to BCR, SH1 tyrosine kinase domain and the coil-coil protein dimerization 
domain. This fusion protein lacks the N-terminal myristoylated region of ABL1 which 
causes autoinhibition of the SH1 kinase activity.  Thus, should we inhibit the 
myristoylated domain-binding pocket we would be doing so in an effective manner, it has 
been done through GNF2 and it has been seen to reduce the emergence of resistant 
mutants (Zhang, et al., 2010). BCR-ABL1 fusion protein promotes aberrances in 
apoptosis, proliferation and cell adhesion (through signalling pathways such as: 
JAK/STAT, PI3K/AKT, Ras/MEK, p53, MYC, beta-catenin, C/EBP𝛼), augmenting the 
proliferation of granulocytes and causing the clinical features seen in the chronic phase 
of CML (Chereda & Melo, 2016). The transition in time towards a blastic phase following 
an accelerated phase, has been proposed to be initiated through BCR-ABL1 genetic 
damage, and inadequate DNA repair machinery (Perrotti, Jamieson, Goldman, & 
Skorski, 2010).  
Treatment.  
We may in first order define what a complete cytogenetic response (CCR) is, which is 
the absence of the Ph in ≥ 20 cells in metaphase in a bone marrow aspirate, and a major 
molecular response (MMR) is reached when 𝑟 =
𝐵𝐶𝑅−𝐴𝐵𝐿1
𝐴𝐵𝐿1
 (where BCR-ABL1 stands for 
the concentration of the chimeric protein) is 𝑟 < 1𝑥10−3 or − log(𝑟) > 3 (Oriana, et al., 
2013). Having these definitions as a preludium, we may say that imatinib mesylate 
stands as the gamechanger in CML and the course of the disease, with a recommended 
dose of 400 mg/day, however different doses have been proposed based upon both the 
MMR and CCR reached with each, the average CCR with imatinib at 400 mg is 57.67% 
and with 800 mg of 65.67%, while the MMR with 400 mg is 36.67% and with 800 mg is 
45% (Aladag & Haznedaroglu, 2019); imatinib is a tyrosine kinase inhibitor which binds 
to the ABL1 portion of the chimeric protein, imatinib binds and stabilises the non-ATP 
binding conformation of BCR-ABL1 kinase domain. Imatinib has been combined in some 
fashions in order to promote synergy of drugs, these other compounds are arsenic, 
interferon-alpha, cytarabine, doxorubicin, leptomycin B, with some enhancements of 
imatinib properties. Resistances to imatinib have been seen and should be early 
characterized in order to escalate doses or to move to second line treatments (Moen, 
McKeage, Plosker, & Siddiqui, 2007).  
Second line treatments are dasatinib and nilotinib, the latter exhibits better CCR and 
MMR (CCR=87%, MMR=71% in 24 months) as well as dasatinib (CCR=86%, 
MMR=82%. A combination treatment of nilotinib and Peg-IFN (interferon used to be the 
frontline treatment of CML before the arrival of imatinib) has been proposed and shows 
good results in 12 months with an MMR=76% and CCR=100%. As third-line treatments, 
there exist some options, such as the allogenic stem cell transplantation, and tyrosine 
kinase inhibitors: bosutinib and ponatinib (Aladag & Haznedaroglu, 2019).   
Several combinations for tyrosine kinase inhibitors (TKI) have been proposed, such as: 
bosutinib or dasatinib or omatinib or nilotinib + IFN-alpha; imatinib + 
hydroxyurea/cytarabine/omacetaxine/homoharringtonine; ascimimib, immune 
modulation (nivolumab + dasatinib, avelumab + TKI), PPARgamma agonists, DPPIV 
inhibitors (Westerweel, te Boekhorst, Levin, & Cornelissen, 2019), other molecules that 
have been used in order to inhibit CML are: arsenic trioxide (as monotherapy), 
hydroxychloroquine, BMS-833923, LDE225, panobinostat, ruxolitinib, zileuton (Bhatia, 
2017). 
Model.  
Hereby one model concerning the stochastic nature of the proteins associated with the 
fusion protein BCR-ABL1 in CML is displayed. 
Stochastic model.  
A stochastic model concerning the protein-protein interactions in CML could provides us 
with new ground and opportunities in therapeutic approaches in the short- and long-term 
future, through estimations of the most probable nodes or proteins in the network could 
we direct our efforts in order to develop new and more potent drugs, as well, through 
estimations of mean time of passage we can predict to which node our network tends to. 
This model may as well bring light upon the pathophysiology of the transition towards a 
blastic crisis. We will consider first the BCR protein network alone, followed by the one 
related to the ABL1 protein, and finally we will deem them as a joint set; In the thrice of 
cases, the models are to be discrete time discrete Markov chains.  
The BCR protein has shown interactions with 87 different proteins (TyersLab, 2019), 
these interactions are then a stochastic process with a set of states ?̂? = {𝑃1, 𝑃2, … , 𝑃𝑛} 
where P stands for protein and then we can define a function f, such that 𝑓: ?̂? → 𝑆1 where 
𝑆1 = {𝑠𝑖 ∈ ℤ
+} is a bijective function for the states of proteins. The temporal parameter is 
defined as 𝑇 = {𝑡𝑖 ∈ ℤ
+} where this temporal parameter for the meantime shall be an 
arbitrary time unit. The rules of transition are, 
𝑠𝑖𝑅𝑠𝑖 → 𝑠𝑖  
𝑠𝑖𝑅𝑠𝑗 → 𝑠𝑗 
𝑠𝑗𝑅𝑠𝑖 → 𝑠𝑖 
Where R stands for the presence of a relationship or interaction between de i-th and j-th 
proteins.  
The stochastic matrix of this protein has the following shape, 
𝑃 =
(
 
 
𝑝11 𝑝12 𝑝13 … 𝑝1𝑛
𝑝21 𝑝22 𝑝23 … 𝑝2𝑛
𝑝31
⋮
𝑝𝑛1
𝑝32
⋮
𝑝𝑛2
𝑝33
⋮
𝑝𝑛3
…
⋱
…
𝑝3𝑛
⋮
𝑝𝑛𝑛)
 
 
 
The complete matrix is shown (Fig. 1).  
If we set the initial vector to be at equilibrium, i.e., 𝜋0 =
1
86
(11, … , 186), we may determine 
the distribution at any given moment 𝑡𝑛, according to the following expression, 
𝜋𝑛 = 𝜋0𝑃𝑛 
First, let us find some distributions at selected values of n (Fig. 2). From this we can 
predict what the limit distribution would look like, and we can organize the proteins by 
their limit distribution from greater to lesser, here we will present the proteins in which 
the process will tend to be 95.2973% of the time from there will we be able to determine 
possibilities of directed therapy, and we will represent the information as logic circuits, 
the possible therapies ∀𝑎𝑖 ∈ 𝐴∃𝑏𝑖 ∈ 𝐵|𝐵 = {𝑏𝑖 ∈ ℤ
+} ∧ 𝑓: 𝐴 → 𝐵 where A stands for the 
set of the drugs available.  
The matrix for ABL1 protein is as shown (Fig. 3). We will determine the distributions when 
𝑛 → ∞ for ABL1 (Fig. 4).  
This model provides us with the opportunity to observe the behaviour of the signalling 
networks in CML, more specifically, the probability of every network to be at any given 
state at one moment, interestingly do we notice that neither of both nodal proteins (BCR 
nor ABL1) show a large stationary probability, this invites us to think that therapeutic 
targets in CML is made up from a larger set of molecules than we may have initially 
considered, and that we may be able to deliver a much more complete therapy to CML 
patients in such a way that the backbone treatment is one corresponding to those 
interacting with either BCR or ABL1, but we then have the limbs of the treatment, where 
we can by all means induce a thrust by considering the probability of finding any of both 
systems at any state (of the most probable ones). In order to compute feasible “limb”-
like treatments, we shall consider the drug efficacy of the molecules we will introduce, 
this in turn will allow us to compute the complete or total efficacy of the treatment. This 
feasibility must be taken in account from the stationary probability obtained above, from 
which we shall consider those molecules whose summed up probability equals 0.95, 
such that, 
∑𝜋𝑖
𝑛
𝑖=1
≥ 0.95 
Where 𝜋𝑖 stands for the stationary probability for the system to be in the i-th state, this 
expression let’s us find in which state the systems will be in 95% of the time. For the 
case of BCR protein, this means the available drugs for 63 different proteins (including 
BCR) and for ABL1 this means the equally available drugs for 133 different proteins, the 
first set of drugs let us define it as A and the second one as B,  
|𝐴 ∩ 𝐵| > |∅| 
Moreover, let us define a set C which is the set of all proteins with which BCR interacts 
and D as the set of all proteins with which ABL1 interacts,  
|𝐶 ∩ 𝐷| > |∅| 
Ω1 = {𝐶, 𝐷} 
p(Ω1) = 1 
𝐶 ⊂ 𝐷 
𝐷 ⊂ 𝐶 
∴ 𝐶 ≠ 𝐷 
Currently, the previously described sets, say A and B show the following relationships,  
𝐴 ⊂ 𝐵 
𝐵 ⊂ 𝐴 
∴ 𝐴 ≠ 𝐵 
We define these sets, 
𝐴 ⊆ 𝐶 
𝐴 = {∀𝑎𝑖 ∈ 𝐴|∑𝜋𝑖
𝑛
𝑖=1
≥ 0.95} 
𝐵 ⊆ 𝐷 
𝐵 = {∀𝑏𝑗 ∈ 𝐵|∑𝜋𝑗 ≥ 0.95
𝑚
𝑗=1
} 
Now, we may describe the following probability tree, 
 
Thus, they do share proteins, more specifically, 
|𝐴 ∩ 𝐵| = 167 
If we define a new probability space, Ω2 = {𝐴, 𝐵} with 𝑝(Ω2) = 1, then, this space defines 
those proteins that interact with both BCR and ABL1 proteins: the protein interactions 
corresponding to those of the chimeric protein. We can outline a new Markov chain from 
this probability space, such that the set of states 𝑆2 ⊆ 𝑆1, this set of states is the sum of 
the probabilities in Ω1 is ∑ 𝜋𝑖
𝑛
𝑖=1 = 0.95, nevertheless in Ω2 this sum results ∑ 𝜋𝑖
𝑛
𝑖=1 = 1, 
these states display stationary probabilities and are shown in Fig. 5.  
Discussion.  
Undoubtedly is imatinib the frontline and central treatment in CML, it indeed has changed 
the prognosis landscape for these patients, showing very good results in regards to the 
MMR and CCR, achieving 57.67% in CCR with 400 mg/day and an MMR with 400 
mg/day of 36.67% (Aladag & Haznedaroglu, 2019) with a life expectancy of patients with 
CML of 3 years less than that of the general population and this life expectancy has been 
computed to be always less than that of the general population; moreover, the use of 
imatinib and other TKIs poses a risk predisposing to other cancers and cardiovascular 
morbidity (Bower, et al., 2016). Imatinib as the medullar treatment of CML, and other 
tyrosine kinase inhibitors display as their mechanism of action the binding to the chimeric 
protein BCR-ABL1, whether to the ABL1 portion or to the BCR portion of this protein and 
while they have approximated the life expectancy of patients with CML to that of the 
general population and improved their quality of life, efforts can be made to provide 
alternative therapeutic approaches to CML.  
Through the model previously introduced, we have computed the stationary stochastic 
probabilities of three Markov chains, the ones corresponding to the BCR protein, ABL1 
protein and the chimeric BCR-ABL1 protein; we then selected those proteins whose sum 
of stationary probabilities summed 𝑝 = 0.95, then from those proteins, we computed a 
new chain, the one for the chimeric protein and its stationary probabilities. This showed 
that the network of proteins with which BCR-ABL1 interacts is a vast array composed of 
167 proteins, including themselves, and that this network in the stationary spectrum or 
when the number of steps in time taken when 𝑛 → ∞ does favour the rationale of use of 
TKIs due to the fact that the stationary probabilities for BCR and ABL1 in the chimeric 
protein Markov chain are, 
𝜋𝐴𝐵𝐿1 = 0.07784161 
𝜋𝐵𝐶𝑅 = 0.04530407 
Because these two probabilities are the maxima of the protein array,  
𝜋𝐴𝐵𝐿1 > 𝜋𝐵𝐶𝑅 > 𝜋𝑗 
That is, they are greater than the stationary probability of any other j-th protein in the 
Markov chain. This model provides us with information about how much time the network 
spends on each of the members of the network based upon the interactions they show, 
thus they spend the 𝜋𝐵𝐶𝑅 + 𝜋𝐴𝐵𝐿1 = 0.12314568 of time (𝑡 = 12.31457%) in these 
proteins, but this time is less than the eighth of the time of the network, and if good results 
are achieved through the inhibition of these chimeric protein (or the two states of the 
Markov chain), then the inhibition (or corresponding activation) of interacting proteins 
could improve the results in patients with CML; some proteins that show promises in this 
regard are those that interact both with the BCR part and the ABL1 part of the chimeric 
protein, 𝐵𝐶𝑅 ∩ 𝐴𝐵𝐿1 = 𝐾, where K is the set that contains these proteins: TP53, CBL, 
GRB2, HSPA8, PIK3R1, UBC, SHC1, STUB1, HSP90AA1, CRK, HSPA4, CRKL, RB1, 
PIK3R2, KIAA1429, TRIM25, UBASH3B, NTRK1, SOS1, DOK1, XPO1, AP2M1, 
PTPN6, HSPD1, RAD51, HCK, LRRK1 (with their corresponding stationary probabilities 
shown in Fig. 6) this subnetwork or set of proteins contains the 43.71% of the time spent 
in the network. This approach could be improved by observing the signalling pathways 
in which BCR-ABL1 engages and as we have previously mentioned, the main pathways 
involved in the pathophysiology of CML through BCR-ABL1 are: beta-catenin, C/EBP-
alpha, JAK/STAT, PI3K3/AKT, RAS/MEK, TP53, MYC; and we may from this moment 
regard that some of the aforementioned proteins exist in the Markov chains (TP53, MYC, 
PIK3). 
JAK/STAT pathway.  
In the instance of the JAK/STAT pathway, there exist in the Markov chain of the chimeric 
protein some proteins in turn which play roles in this signalling pathway, e.g.: JAK1, 
SOCS1, SOCS3, SOS1, GRB2, MYC, PIK3R1, PTPN6, PIK3R2, EGFR, PDGFR 
(Rawlings, Rosler, & Harrison, 2004); by inhibiting JAK1 activity we could effectively 
inhibit the signalling pathway, or by means of promoting the transcription of SOCS1 or 
SOCS3 which effectively inhibit JAK1 through a negative feedback fashion, 
 
By inhibiting JAK1 would we be targeting 𝑝 = 0.00298422 of the network involved in the 
chimeric protein, but because of its various interactions, this probability would sum up to 
𝑝 = 0.11778089, which would represent a larger inhibition than that represented by the 
inhibition of BCR or ABL1 on their own; several JAK1 inhibitors have been described, 
such as ruxolitinib (TyersLab, 2020) and other JAK1-selective inhibitors: filgotinib, 
GLPG0555, GSK2586184, INCB039110, INCB47986, ABT-494; said inhibitors 
encounter themselves in clinical phases I, II, IIb and on hold (Menet, Mammoliti, & López-
Ramos, 2015). Alternative manners to achieve suppression of JAK1 signaling pathway 
involve the JAK1-independent promotion of expression of SOCS1/3, the one for SOCS1 
has been performed elsewhere through the administration of interferon-gamma 
(Madonna, et al., 2015). EGFR inhibitors are currently used in different types of cancer 
(e.g.: non-small cell lung cancer) and are classified in three generations, some of these 
drugs are: gefitinib, erlotinib, afatinib, dacomitinib, neratinib, osimertinib, rociletinib, 
olmutinib, ASP8273, nazartinib, avitinib; some of which are either in phases I, II or III and 
some others have already been approved (Sullivan & Planchard, 2017).  
TP53 pathway.  
TP53, when activated is due to the cellular response to an insult, either in nutrition, low 
oxygen levels, DNA damage, etc., this activation turns in change in the expression of 
genes corresponding to cellular senescence and apoptosis, it has been seen that TP53 
is activated by ATR and ATM (by means of a third party protein not involved in the main 
protein network) and inactivated my MDM2 (Kanehisa Laboratories, 2018), the main 
network spends 5.196799% of its time in this subnetwork and is a feasible target in CML 
therapy, either by means of TP53 activation, MDM2 inhibition or ATM and ATR 
activation. As MDM2 inhibitors we could readily use nutlin-3 a small molecule which has 
been studied as a therapy in some cancers in combination with other drugs, such as 
1,25-dihydroxyvitamin D(3), AZD6244, PI-103, MK-0457, perifosine, dasatinib, 
doxorubicin, platinum compounds (Shen & Maki, Pharmacologic activation of p53 by 
small-molecule MDM2 antagonists., 2011). ATR activation can be mediated through the 
administration of hydroxyurea, which has been shown to perform its action by means of 
increasing replication stress (Landsverk, et al., 2019).  
Beta-catenin pathway.  
It involves the primary condition of whether there are any Wnt ligands that may activate 
DVL, if the condition is not sufficed, the destruction complex will promote the 
ubiquitination of CTNNB1 (beta-catenin), this is possible through four proteins: APC, 
GSK3B, CK1, axin. If the condition is sufficed, the destruction complex will be inhibited 
by DVL, more specifically, DVL will inhibit the actions of GSK3B and thus of the whole 
complex; with this inhibition, CTNNB1 is free to roam into the nucleus and promote the 
expression of genes like MYC and cyclin D1 (Krishnamurthy & Kurzrock, 2018). The 
inhibition of this pathway would represent the inhibition of 1.918889% of the BCR-ABL1 
chimeric protein network and may be done through a series of either inhibitions or 
activations; we may inhibit the WNT ligands, DVL, or CTNNB1; or we may promote either 
the expression or the function of APC, GSK3B, CK1, axin. Regarding DVL inhibitors, we 
have some options, such as: niclosamide, sulindac, NSC668036, J01-017a. Now, with 
CTNNB1 we have some options, such as the inhibitors of the co-activators: ICG-001, 
PRI-724; and those of the DNA binding: PKF115-584, PKF118-310 (Krishnamurthy & 
Kurzrock, 2018).  
Combination therapies.  
In this instance, we propose imatinib or a TKI of second- or third-line of treatment as the 
cornerstone of therapy, however, because this represents the inhibition of 12.314568% 
of the network (directly), we propose the use of a branched treatment in order to promote 
the inhibition of this network’s signalling, 
Cornerstone 
drug.  
Branch drug.  Inhibition 
probability.  
Imatinib.  + 
 
 𝑝 =
0.12314568  
 JAK/STAT 
pathway 
inhibitors. 
• JAK1 
inhibitors.  
• SOCS1 
expression 
promoters.  
• EGFR 
inhibitors.  
+ 
 𝑝
= 0.24092657 
  TP53 
pathway 
activators.  
• ATR 
activators.  
• MDM2 
inhibitors.  
• TP53 
activators.  
+ 𝑝
= 0.29289456 
 CTNNB 
pathway 
inhibitors.  
• DVL 
inhibitors.  
• GSK3B 
activators.  
• CTNNB1 
inhibitors.  
𝑝
= 0.31208345 
 
Final remarks.  
The prognosis for patients with CML has improved by means of the introduction of 
imatinib into its treatment, with the advent of different tyrosine kinase inhibitors, 
resistance in patients could be adverted; however, goals in both the MMR and CCR in 
patients with CML remain low as well as the diminishment in life expectancy of these 
patients versus the general population, in this paper we have attempted to provide a 
Markov chain model to predict the most probable interactions within the networks of the 
proteins involved in the pathogenesis of CML: BCR, ABL1 and the chimeric protein BCR-
ABL1; and by observing the signalling pathways affected by the aberrant behaviour of 
the chimeric protein we could devise some adjuvant or “branch”-like therapies to the 
cornerstone one (tyrosine kinase inhibitors) in order to augment the probabilities of 
patients for a longer life expectancy, quality of life and diminishment in incidence of 
blastic crises, which severely endanger life.  
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Set of 
molecule/molecule.  
Chromosome 
location.  
Comments.  
ɐ Metabolism.  
HSPA8.  11q24.1 It is a member of the heat shock protein family 
A, functioning as a chaperone binding to newly 
formed peptides for their appropriate folding; 
possesses functions in vesicle disassembly 
(NIH, 2019). BCR-ABL1 has been seen to 
induce the expression of this protein in CD34(+) 
CML cells which forms complexes with different 
gene products induced as well by the fusion 
protein: CCND1, CDK4 which may contribute to 
the abnormal proliferation of CML cells (San 
José-Enériz, et al., 2008).  
USP15. 12q14.1 Ubiquitin specific peptidase 15 (USP15), is a 
member of the family of deubiquinitating 
enzymes, it also associates with the COP9 
signalosome and shows a role in the 
deubiquitination of SMAD transcription factors 
(NIH, 2019). This protein has been reported to 
be amplified in breast, ovarian cancer and 
glioblastoma tumours regulating the TGF-beta 
transcription pathway (Pal & Donato, 2014)   
HSP90AA1. 14q32.31 Heat shock protein pertaining 90 alpha family 
with chaperone functions in its homodimer form, 
this functions are performed throughout the use 
of an auxiliary ATPase activity (NIH, 2019), it 
has been related to some signalling pathways in 
cancer cells, and as well it has been seen to 
regulate the expression of BCR-ABL1, thus 
could we approach the inhibition of this protein 
to diminish the expression of BCR-ABL1 fusion 
protein (Shen, et al., 2014).  
UBC. 12q24.31 It is a ubiquitin gene, thus it has been associated 
with protein degradation, DNA repair, cell cycle 
regulation, kinase modification, endocytosis and 
other pathways (NIH, 2019), has it established 
been that ubiquitination of BCR-ABL1 may be an 
upcoming therapeutic target in the treatment of 
CML (Ru, et al., 2016).  
WDR48. 3p22.2 This protein interacts with ubiquitin specific 
peptidase 1, activating this protein’s activity 
removing ubiquitin from FANCD2 which is in turn 
ubiquitinated in response to DNA damage (NIH, 
2019); WDR48 has been seen in Ph(-) clones of 
myeloproliferative neoplasms fused to PDGFRB 
(platelet-derived growth factor receptor beta) 
(Hidalgo-Curtis, et al., 2009).  
ERCC3. 2q14.3 This gene encodes a DNA helicase ATP-
dependent that functions in nucleotide excision 
repair, it is a subunit of basal transcription factor 
2, and it functions in class II transcription. It has 
been associated to diseases such as: 
xeroderma pigmentosum B, Cochayne’s 
syndrome, trichothiodystrophy (NIH, 2019).  
PIK3R1. 5q13.1 It encodes a protein which functions as a 
regulatory subunit to the phosphoinositide-3-
kinase which phosphorylates the inositol ring f 
phosphatidylinositol at 3’. Plays a role in the 
metabolic actions of insulin, and it has been 
associated to insulin resistance (NIH, 2019). 
Moreover, has it been seen that BCR-ABL1 
induces TGF-𝛽1-activated PI3K signalling which 
promotes the release of s-KitL and s-ICAM1 
which in turn augments the presence of tumour 
stem cells in peripheral circulation (Li, et al., 
2015).   
PDZK1. 1q21.1 This gene contains a PDZ-domain, deriving from 
it its name, being this protein a scaffolding 
protein. These class of molecules binds to and 
mediates the subcellular localization of target 
proteins, in this case it mediates the localization 
of cell surface proteins, and amongst the 
proteins whose localization regulates we may 
find HDL receptor, thus having a role in 
cholesterol metabolism. It has been associated 
with metabolic syndrome and resistance of 
multiple myeloma (NIH, 2019). Recently, it was 
shown that BCR binds to PDZK1 at the 
junctional region of epithelial cells, which in turn 
may affect Ras signalling (Malmberg, et al., 
2004).  
COMMD1. 2p15 The encoded protein is a regulator of cooper 
homeostasis, sodium uptake and NFKB 
signalling (NIH, 2019). Cellular stress due to 
BCR-ABL1 has been related to nucleoli 
disruption and increase in COMMD1 expression 
(Chen & Stark, 2019).  
TP53. 17p13.1 It is a tumour suppressor protein which may 
activate transcription, bind to DNA and 
oligomerize. It responds to cellular stresses, 
thus being able to induce cycle arrest, 
apoptosis, senescence, DNA repair, change 
metabolism. This protein has been related to 
many forms of cancer, including hereditary ones 
(NIH, 2019). TP53 has been associated to 
imatinib in CML cases (Wendel, et al., 2006).   
MAOA. XP11.3 Monoamine oxidase A is a mitochondrial 
enzyme which catalyzes the deamination of 
amines. A mutation in this gene could induce 
Brunner syndrome, and a plethora of psychiatric 
disorders (NIH, 2019). Inhibiting MAOA could in 
turn disrupt the blood-brain barrier and then 
promote a better delivery of imatinib to the CNS 
compartment (Kast & Focosi, 2010).  
MCM2. 3q21.3 It is a minichromosome maintenance complex 
component, part of a family of proteins which are 
highly conserved and are involved in the 
initiation of eukaryotic genome replication, it 
regulates the helicase activity of the complex, 
and it is regulated by protein kinases CDC2 and 
CDC7 (NIH, 2019).  
NAGK. 2p13.3 N-acetylgucosamine kinase is the major 
enzyme which recovers amino sugars and 
catalyzes the conversion of N-acetyl-D-
glucosamine to N-acetyl-D-glucosamine 6-
phosphate (NIH, 2019). NAGK expression has 
been inversely correlated with cellular viability 
(Iorns, et al., 2009).  
ɐ Signal 
processing.  
  
CSNK2A2. 16q21 It is a casein kinase 2 which phosphorylates 
acidic proteins; involved in several cellular 
processes: cell cycle, apoptosis, circadian 
rhythms. An intronic variant could be associated 
with leukocyte telomere length in South Asian 
population (NIH, 2019).  
TRIM25. 17q22 Member of the tripartite motif family, it localizes 
to the cytoplasm and may function as a 
transcription actor; its expression is promoted by 
oestrogen (NIH, 2019).   
HCK. 20q11.21 Member of Src family of tyrosine kinases, with 
hemopoiesis functions in the myeloid and B-
lymphoid lineages, in the respiratory burst, 
neutrophil migration and neutrophil 
degranulation (NIH, 2019).  
FES. 15q26.1 Human cellular counterpart of a feline sarcoma 
retrovirus protein, with tyrosine kinase activity. 
Its chromosomal location has been linked to a 
translocation occurred in patients with acute 
promyelocytic leukaemia, but also involved in 
hemopoiesis and cytokine receptor signalling 
(NIH, 2019).  
CBL. 11q23.3 Proto-oncogene that encodes a RING finger E3 
ubiquitin ligase, one of the enzymes necessary 
for targeting substrates for degradation by 
proteasome, by means of transfer of ubiquitin 
from ubiquitin conjugating enzymes. It may also 
interact with tyrosine-phosphorylated substrates 
for their degradation by proteasome. When 
translocated, it could lead to acute myeloid 
leukaemia (NIH, 2019).  
CRK. 17p13.3 Proto-oncogene that binds to tyrosine-
phosphorylated proteins, it possesses two 
domains with counteracting abilities of 
transformation (NIH, 2019).  
KIT. 4q12 It is a proto-oncogene, type 3 transmembrane 
receptor for MGF; mutations in this gene have 
been associated with various diseases: 
gastrointestinal stromal tumours, mast cell 
disease, acute myelogenous leukaemia (NIH, 
2019). 
DOK1. 2p13.1 Docking protein 1, is a protein which engages in 
the downstream signalling pathway of tyrosine 
kinases, being this protein a scaffold protein 
which assists in the assembly of signalling 
complexes (NIH, 2019).  
ERBB2IP. 5q12.3 ERBB2 interacting protein contains a PDZ 
domain and binds to the unphosphorylated form 
of ERBB2 protein, regulating it. This protein 
affects Ras signalling (NIH, 2019).  
SOS1. 2p22.1 It is a guanine nucleotide exchange factor for 
RAS proteins. By binding to GTP it activates 
RAS proteins and by its binding to hydrolysed 
GTP, it inactivates RAS proteins. It’s been 
associated with gingival fibromatosis 1 and 
Noonan syndrome type 4 (NIH, 2019).  
SLA2. 20q11.23 Part of the SLAP family of adapter proteins, and 
may downregulate T and B-cell mediated 
9responses (NIH, 2019).  
WEE1. 11p15.4 This is a nuclear protein, a tyrosine kinase 
catalysing the phosphorylation of CDC2/cyclin B 
kinase resulting in inhibition of the complex and 
mediates the coordination of transition between 
DNA replication and mitosis (NIH, 2019).  
PTPN6. 12p13.31 Member of the protein tyrosine phosphatase 
family, a signalling molecule involved in cell 
growth, differentiation, mitotic cycle and 
oncogenic transformation. This member is 
expressed in a predilect fashion in 
hematopoietic cells (NIH, 2019).  
TULP3. 12p13.33 Member of the tubby gene family of bipartite 
transcription factors. This protein binds to 
phosphoinositides and functions as a 
transcription regulator that translocates to the 
nucleus when the phosphoinositide molecule 
hydrolyzes, thus playing a role in neuronal 
development and its function (NIH, 2019).  
ɐ Structure.   
MLLT4. 6q27 Multi-domain protein that plays a role in 
signalling and organization of cell junctions, and 
it has also been seen as a fusion partner of 
acute lymphoblastic leukemic gene, which takes 
part in acute myeloid leukaemias (NIH, 2019).   
EZR. 6q25.3 Ezrin is the encoded protein by this gene, a 
membrane protein which functions as a tyrosine 
kinase substrate in microvilli, plays a role in cell 
surface adhesion, migration and organization. It 
has been associated with various cancers (NIH, 
2019).  
JPH4. 14q11.2 Member of the junctophilin family of 
transmembrane proteins, involved in junction 
adhesions (NIH, 2019).  
RSPH9. 6p21.1 Protein component of radial spoke head in cilia 
and flagella. Mutations in this gene have been 
associated with primary ciliary dyskinesia 12 
(NIH, 2019). 
SYNC. 1p35.1 Member of the intermediate filament family, with 
a high expression pattern in skeletal and cardiac 
muscle. It links the dystrophin associated protein 
complex to desmin filaments (NIH, 2019). 
ɐ Cell trafficking.   
AP2M1. 3q27.1 Subunit of the heterotetrameric coat assembly 
protein complex 2, this protein is required for the 
activity of a v-ATPase, which conduces to 
acidification of endosomes and lysosomes, it 
has a role in intracellular trafficking and CTLA4 
protein function regulation (NIH, 2019).  
ɐ Cell growth.   
GRB2. 17q25.1 This protein binds the epidermal growth factor 
receptor, and one of its domains binds tyrosine 
phosphorylated sequences (NIH, 2019).  
TSG101. 11p15.1 Homolog of ubiquitin-conjugating enzymes, it 
interacts with stathmin, a phosphoprotein 
implicated in tumorigenesis. It plays a role in cell 
growth and differentiation and it is a negative 
growth regulator. It plays a role in genomic 
stability and cell cycle regulation (NIH, 2019).  
ɐ Cell 
proliferation. 
  
ɐ TP53.  Idem sup.  Idem sup.  
 
Table 1. BCR-ABL1 fusion protein interacts with various other molecules, a selection of them along with a small description of them is shown 
above, shedding light about the targets this protein possesses, and the possible roles of these proteins in the development of the disease.  
 
 
 
 
 
 
 
 
 Fig. 1. Graph depicting the stochastic matrix of the BCR protein interactions; in the y-axis we may find the initial state protein and the x-axis 
represents the molecule towards each of the i-th initial molecule/state will move to in the next step.  
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 Fig. 2. Stationary probability distributions of the BCR protein interactions, with the x-axis depicting the molecules with which BCR interacts, the y-
axis the corresponding probability and the different coloured lines, the values of iteration or steps considered to compute the distribution.  
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 Fig. 3. Graph which represents the stochastic matrix of the ABL1 protein interactions.  
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 Fig. 7. Network showing the JAK/STAT signalling pathway (Rawlings, Rosler, & Harrison, 2004) and the potential sites of its inhibition: JAK1 
inhibition by filgotinib (depicting one of many drugs which could be potentially used) (PubChem, 2020), gefitinib as an EGFR inhibitor (PubChem, 
2020) and IFNG as a promoter of SOCS1 expression.  
